Broughton welcomes FDA authorisation of ZYN nicotine products

Broughton Welcomes FDA Authorisation of ZYN Nicotine Pouches 

Broughton, a leading contract research organisation specialising in reduced-risk nicotine products, welcomes the US Food and Drug Administration’s (FDA) decision to authorise ZYN nicotine pouches for sale. This critical milestone underscores the importance of science-based tobacco harm reduction and provides adult smokers with a viable alternative to combustible cigarettes. 

Nicotine pouches, a modern oral nicotine product (MONP), eliminate the harmful by-products of combustion, offering smokers a safer path towards quitting traditional cigarettes. However, the industry still faces challenges in ensuring these products are responsibly marketed and rigorously regulated. 

Chris Allen, CEO of Broughton, commented: “This FDA authorisation is a significant step forward in tobacco harm reduction, demonstrating the vital role of scientifically validated products in providing consumers with less harmful options. At Broughton, we are committed to supporting the development of innovative nicotine products that can transform public health outcomes.” 

With smoking-related illnesses claiming over 8 million lives annually, reduced-risk products like nicotine pouches represent a pivotal opportunity to change the global health landscape. Sweden’s success in achieving smoke-free status through a balanced approach to regulation and alternative products demonstrates what is possible when innovation and harm reduction go hand in hand​​. 

Broughton partners with nicotine innovators to deliver comprehensive regulatory and scientific consultancy, ensuring reduced-risk products meet the highest standards of safety and efficacy. With expertise spanning toxicological risk assessments, behavioural studies, and regulatory submissions, Broughton is the trusted partner for companies navigating the complex PMTA process. 

Through tailored strategies, extensive FDA insight, and a proven track record of PMTA Marketing Order successes, Broughton streamlines the path to compliance, enabling manufacturers to bring innovative oral nicotine products to the US market with confidence.  

For any business considering a PMTA submission for oral nicotine products, Broughton offers the expertise, strategic guidance, and regulatory knowledge needed to succeed while contributing to global tobacco harm reduction efforts. 

For more information about Broughton’s PMTA services, visit https://www.broughton-group.com/premarket-tobacco-product-application 

Ends: 314 words 

Image caption: 

For further information contact:  

Telephone: +44 1282 570524 

www: https://www.broughton-group.com/  

e-mail: rskelton@broughton-group.com  

LinkedIn: https://www.linkedin.com/company/broughton-group/   

Press enquiries: Patrick Ball and Ian Bolland 

Suites 1 and 2, The Malthouse, Water Street, Stafford, Staffordshire, ST16 1AR 
Telephone: +44 (0) 1785 225416 

e-mail:  patrick@stonejunction.co.uk and ian@stonejunction.co.uk  

www: https://www.wechangeminds.com/  

About Broughton Group: Broughton is an independent life sciences contract research organization serving a global roster of clients from the UK, Europe, North America, the Middle East, Asia, and Australia. We offer high-quality in-house analytical testing services integrated with scientific consultancy and global regulatory support. Our in-house laboratory testing facilities are GMP compliant and ISO/IEC 17025 accredited. We are regularly inspected by the Medicines and Healthcare products Regulatory Agency (MHRA), the US Food and Drug Administration (FDA), and the United Kingdom Accreditation Service (UKAS). 

With over 15 years of scientific experience and a world-leading team of scientific and regulatory consultants, we support our partners in bringing innovative products to market to deliver better health outcomes. 

Ref: BRO419/12/24